Results from study of Inspire Upper Airway Stimulation (UAS) System in obstructive sleep apnea published in Otolaryngol Head Neck Surg journal- Inspire Medical Systems

Inspire Medical Systems has announced the results of a landmark long-term clinical study for its Inspire Upper Airway Stimulation (UAS) System, the first FDA-approved implantable neurostimulation treatment for people diagnosed with Obstructive Sleep Apnea (OSA). The Stimulation Therapy for Apnea Reduction (STAR) trial was conducted at 22 leading sleep medicine centers across the United States and Europe. One-year STAR trial outcome measures, published in the New England Journal of Medicine in 2014, showed that sleep apnea patients receiving Inspire therapy experienced significant reductions in sleep apnea events and significant improvements in quality of life measures. The new long-term study outcomes showed that the improvements observed at one-year were sustained at the three-year follow up mark.

The outcomes include a 78 percent reduction in apnea-hypopnea index (AHI) from baseline, an 80 percent reduction in oxygen desaturation events from baseline, an 80 percent of bed partners reported soft or no snoring as compared to 17 percent of bed partners at baseline and Quality of life measures, including daytime sleepiness and functioning, showed clinically meaningful improvements and a return to normal levels over baseline. The results were published in the online issue of Otolaryngology – Head and Neck Surgery.